The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
June 12, 2023
View Complete Issue         Table of Contents 2019 
Asciminib (Scemblix) for Chronic Myeloid Leukemia (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Asciminib (Scemblix) for Chronic Myeloid Leukemia (online only)
June 12, 2023 (Issue: 1678)
Asciminib (Scemblix – Novartis), an oral kinase inhibitor, has been approved by the FDA for treatment of adults with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) in chronic phase (CP) previously treated with ≥2 tyrosine...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Asciminib (Scemblix) for Chronic Myeloid Leukemia (online only)
Article code: 1678g
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.